Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
A phase III trial conducted by Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with advanced non-small-cell lung cancer. Three regimens were compared: cisplatin/etoposide, paclitaxel/ cisplatin/granulocyte colony-stimulating factor (G-CSF), and paclitaxel/ cisplatin. Patients were randomly assigned to the regimens, each of which was repeated every 21 days over a 17-month period. Response rates were 12% in the cisplatin/etoposide group, 31% in the paclitaxel/cisplatin/G-CSF group, and 26% in the paclitaxel/cisplatin group. Significant differences in response were observed between the cisplatin/etoposide and paclitaxel/cisplatin/G-CSF groups and the cisplatin/etoposide and paclitaxel/cisplatin groups; there was no significant difference between patients treated with paclitaxel/cisplatin vs paclitaxel/cisplatin/G-CSF. Both paclitaxel regimens were associated with significantly higher response rates compared with etoposide/cisplatin. Based on preliminary survival analyses, the investigators concluded that the paclitaxel regimens may be associated with superior survival.
Bonomi
P
P
Section of Medical Oncology, Rush University Medical Center Chicago, Illinois 60612, USA.
Kim
K
K
Kusler
J
J
Johnson
D
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage
D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin